

## DECREASED EXPRESSION RATIO OF ESTROGEN RECEPTOR-B AGAINST ESTROGEN RECEPTOR-A IN THE BLADDER OF RATS WITH PARTIAL BLADDER OBSTRUCTION

### Hypothesis / aims of study


The effect of estrogen is mediated via its intracellular receptors; the estrogen receptor (ER)- $\alpha$  and the ER $\beta$ . It has recently been reported that ER $\beta$  have a crucial role in anti-inflammatory effects in the brain, uterus, heart and skin, leading to anti-tissue remodelling [1]. It is also known that the decrease of ER $\beta$  is a main cause of inflammation in the central nerve system (CNS). Therefore, ER $\beta$  becomes a therapeutic target in patients with degenerative CNS diseases such as multiple sclerosis and Parkinson's disease [2]. Furthermore, the ER $\alpha$ /ER $\beta$  ratio is shifted to the ER $\alpha$  side in pathological conditions such as uterine adenomyosis. Even though ER $\beta$  is the predominant receptor in the bladder, it is not known whether changes in the expression of ER $\alpha$  and/or ER $\beta$  are involved in the development of bladder dysfunction. Therefore, we investigated the changes in ER $\alpha$ , ER $\beta$  and other related molecules in rat bladders with partial bladder outlet obstruction (BOO).

### Study design, materials and methods

Female 8 weeks old SD rats were divided into BOO (n=5) and control groups (n=5). In the BOO group, the proximal urethra was exposed via a lower abdominal incision under isoflurane anaesthesia. The urethra was intubated with a PE-50 catheter, and a 4-0 silk ligature was placed loosely around the proximal urethra, producing a partial urethral obstruction, and the catheter was then removed. The control group underwent a sham operation without urethral ligation. Three weeks after surgery, awake cystometry was performed, and urodynamic parameters were evaluated, including non-voiding contraction (NVC), pressure threshold (PT), maximum voiding pressure (MVP) and post-void residual volume (RV). After cystometry, the bladder was excised, and separated into mucosa and detrusor muscle layers under a microscope. The mRNA expression levels of ER $\alpha$ , ER $\beta$ , tumor necrosis factor- $\alpha$  (TNF $\alpha$ ), NF- $\kappa$ b, collagen I and connexin-43 (Cx43) were investigated by RT-PCR.

### Results

PT, RV, MVP and the number of NVCs were significantly increased in BOO rats compared with control rats ( $P < 0.05$ ). In detrusor muscle, the mRNA expression of ER $\alpha$ , ER $\beta$ , TNF $\alpha$ , NF- $\kappa$ b, collagen I and Cx43 were significantly increased in BOO rats compared with control rats ( $P < 0.01$ ). Furthermore, The ER $\alpha$ /ER $\beta$  ratio in detrusor muscle was increased in BOO rats vs. control rats ( $P < 0.01$ ) (Figure). On the other hand, in the mucosa, there was no significant difference in ER $\beta$  mRNA expression between BOO and control rats.



### Interpretation of results

These results suggest that BOO induces bladder overactivity as shown by NVCs during urine storage, which is possibly induced by upregulation of Cx43 via activation of NF- $\kappa$ b signalling pathways in detrusor muscle, and that the decrease of ER $\beta$  ratio against ER $\alpha$  could be involved in activation of NF- $\kappa$ b and TNF $\alpha$ , which leads to tissue remodeling evidenced by increased collagen I. Therefore, activation of ER $\beta$  and/or inhibition of ER $\alpha$  could be effective for reducing bladder overactivity and remodeling after BOO.

### Concluding message

Imbalance of ER $\alpha$  and ER $\beta$  expression (i.e., increased ER $\alpha$ /ER $\beta$  ratio) in detrusor muscle could contribute to bladder overactivity and remodeling after BOO. Therefore, activation of ER $\beta$  and/or suppression of ER $\alpha$  could be effective for treating BOO-associated bladder dysfunction. Especially, the ER $\beta$  might be an effective target for the treatment of patients with BOO because ER $\beta$  activation reportedly has therapeutic effects on tissue inflammation and remodeling [1].

### References

1. Am J Physiol Regul Integr Comp Physiol. 2010;298:1597-606.
2. Proc Natl Acad Sci USA. 2013;110:3543-8.

### Disclosures

**Funding:** NIH p01 DK093424 and DK88836 **Clinical Trial:** No **Subjects:** ANIMAL **Species:** Rat **Ethics Committee:** The University of Pittsburgh Institutional Animal Care and Use Committee